Alvotech (ALVO) Earnings Call Transcripts
Alvotech's Latest Earnings Call - June 10, 2026
In the Q2 2026 earnings call, Alvotech (ALVO:US) highlighted significant progress in its biosimilar pipeline, particularly with the FDA's acceptance of its biosimilar to Entyvio and the resubmission of its BLA, setting a potential approval timeline for December 2026. The company reported a strong commercial execution strategy, with expectations of launching five products in the U.S. market, including Eylea and Simponi, amidst a growing total addressable market (TAM) estimated at $250 billion. Management maintained a positive outlook, emphasizing a critical inflection point for growth, although analysts raised concerns regarding regulatory approvals and competitive pressures in the biosimilar landscape.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | |
| Earnings | |
| BLA Resubmission Date | June 4, 2026 (positive) |
| Total Addressable Market (TAM) | $250 billion (positive) |
| Product Launches | 5 (positive) |
| Market Share in Humira | (positive) |
Guidance from management
Management expressed confidence in upcoming approvals and highlighted a potential approval timeline for Entyvio by December 2026. They maintained a positive outlook on growth opportunities in the biosimilar market.
What management said
I think if you look at what -- almost all our peers have done in a similar circumstance, Ash, there's limited information that we would give out, right? Because this is an ongoing process sometimes it could be an ongoing process. We'd love to provide some updates, but unlikely that we'll provide an update before the approval comes through on December.
If there's something incrementally that we can provide some color to for investors, if there is scope for anything at all, we will always be happy to look at it. But at this point, there's nothing that I can guide towards.
What analysts pressed on
Analysts expressed concerns about the regulatory approval process and the competitive landscape for Alvotech's biosimilars. There were questions regarding the timing of approvals and potential market dynamics as competitors enter the space.
Main topics on the call
- Regulatory Progress — Alvotech announced the FDA's acceptance of its biosimilar to Entyvio, with a resubmission of the BLA completed on June 4, 2026, setting a 6-month review clock. Balaji Prasad stated, "We feel extremely confident about it,...
- Product Pipeline Expansion — The company is preparing to launch five products in the U.S. market, including Eylea and Simponi, with management noting that "5 or 6 of our next 8 launches will be into a limited competition field." This positions Alvot...
- Commercial Strategy — Alvotech's B2B model and partnerships, particularly with Teva, are critical for market access. Prasad emphasized, "Speed and execution play a big role," highlighting the importance of being first to market to capture mar...
- Market Opportunity — Management discussed a significant TAM of $250 billion with over 80 product opportunities opening up in the next five years, reinforcing the company's growth potential. Prasad noted, "The next 5 years looks to be extreme...
Read the full Alvotech transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Alvotech
Alvotech (ALVO) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 26 calls on record spanning March 2, 2023 to June 10, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 26 Alvotech earnings call transcripts on record, spanning March 2, 2023 to June 10, 2026. Based on this history, Alvotech reports quarterly. The most recent call on file is dated June 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- ALVO
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 26
- First call
- March 2, 2023
- Most recent
- June 10, 2026
- Reporting cadence
- quarterly